Latest Articlesddd
Gilead Sciences (GILD) has news that begins with an announcement today that Japan’s Ministry of Health, Labour and …
Earlier this month the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CTX001 for …
Why Loxo Oncology and Sage Therapeutics Have Occupied Today's Headline News LOXO Oncology Eli Lilly (LILY) announced its …
Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focused on the development and commercialization of therapeutics for …
Bristol-Myers Squibb (BMY) will acquire Celgene (CELG) in a cash and stock transaction with an equity value of …
The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …
We have a few small clinical stage firms in the Prohost Portfolio that were established with the …
Gilead Sciences (GILD) and Scholar Rock Holding Corporation (SRRK) announced entering into a strategic collaboration to discover and develop …
We Wish You A Happy Spiritual Season and A Happy New Year 2019. We Hope that …
Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD). …
Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech about licensing rights to potential therapeutic small …
During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s …
In the NEWS AstraZeneca (AZN) announced a collaboration with Cancer Research UK to launch a center …
The Chinese National Medical Products Administration (NMPA) has approved Gilead’s (GILD) HIV combination product Descovy®. In China, Descovy is …
Amgen Higher Dividends For those who invest in top-tier biotech firms for dividend payments, in addition …
The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …
Marinus Pharmaceuticals (MRNS) announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV), the …
Today, the market took another beating as a result of either an intentional or an unintentional …
Exelixis (EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib …
Another reason was found to hit the market when the economy is good and sustained and …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
